Stock Events

Stock Events

Formycon 

€17.86
45
-€0.24-1.33% Friday 15:06

Statistics

Day High
17.98
Day Low
17.98
52W High
80.2
52W Low
17.8
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q1 2023
Q3 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Next
-6.27
-2.59
1.08
4.75
Expected EPS
N/A
Actual EPS
N/A

Financials

-145.46%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
44.48MRevenue
-64.7MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0W4N.LSE. It's not an investment recommendation.
Microsoft
6
MSFT
Amazon
6
AMZN
NVIDIA
5
NVDA
Novo Nordisk
5
NOV.XETRA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap293.94B
Novartis AG, through its Sandoz division, is a leading company in developing and marketing biosimilars, making it a direct competitor to Formycon.
AMGEN
AMGN
Mkt Cap196.12B
Amgen Inc. is a biotech firm that develops biosimilars, competing in the same space as Formycon.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. has a strong presence in the biosimilar market, directly competing with Formycon's product offerings.
Biogen
BIIB
Mkt Cap29.4B
Biogen Inc. operates in the biotechnology field, focusing on innovative therapies, including biosimilars, which puts it in competition with Formycon.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. is involved in the development and commercialization of biosimilars, competing with Formycon's biosimilar development efforts.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie Inc. competes in the biosimilar market, particularly in therapeutic areas that overlap with Formycon's interests.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries Ltd. is a global player in generic and specialty medicines, including biosimilars, making it a competitor to Formycon.
Sandvik AB
SAND.ST
Mkt Cap490.34B
Sandoz, a division of Novartis, is a leader in biosimilars and directly competes with Formycon in developing and marketing these products.

About

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Show more...
CEO
Dr. Stefan Glombitza
Employees
203
Country
Germany
ISIN
DE000A1EWVY8

Listings

STU
DE
FYB.STU
MU
DE
FYB.MU
LSE
GB
0W4N.LSE
XETRA
DE
FYB.XETRA

0 Comments

Share your thoughts

FAQ

What is Formycon stock price today?▼
The current price of 0W4N.LSE is €17.86 EUR — it has decreased by -1.33% in the past 24 hours. Watch Formycon stock price performance more closely on the chart.
What is Formycon stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on London Exchange exchange Formycon stocks are traded under the ticker 0W4N.LSE.
Is Formycon stock price growing?▼
0W4N.LSE stock has fallen by -6% compared to the previous week, the month change is a -10.61% fall, over the last year Formycon has showed a -39.35% decrease.
When is the next Formycon earnings date?▼
Formycon is going to release the next earnings report on August 12, 2026.
What were Formycon earnings last quarter?▼
0W4N.LSE earnings for the last quarter are -3.09 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Formycon revenue for the last year?▼
Formycon revenue for the last year amounts to 44.48M EUR.
What is Formycon net income for the last year?▼
0W4N.LSE net income for the last year is -64.7M EUR.
How many employees does Formycon have?▼
As of July 19, 2026, the company has 203 employees.
In which sector is Formycon located?▼
Formycon operates in the Manufacturing sector.
When did Formycon complete a stock split?▼
Formycon has not had any recent stock splits.
Where is Formycon headquartered?▼
Formycon is headquartered in Planegg, Germany.